Pembrolizumab

biologic · immune-hematologic · IV

Pembrolizumab, a biologic. Humanised IgG4 mAb binding PD-1 on T cells → blocks PD-L1/L2 inhibitory signals → releases 'braked' T cells to attack… IV half-life 23 d.

Humanised IgG4 mAb binding PD-1 on T cells → blocks PD-L1/L2 inhibitory signals → releases 'braked' T cells to attack tumour. Tumour-agnostic approval for MSI-high tumours (2017) was an FDA first. ~30+ cancer indications across every anatomic site. Revolutionised oncology.

Pharmacokinetics

• IV — t½ 23.0 d · F 100% · Vd 6.3 L

Sources: PMID:27863186, PMID:31402780